5/10/2025

Janusmed kön och genus

Janusmed kön och genus – Tarceva F.C

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Erlotinib

Erlotinib

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  3. Socialstyrelsen. Cancer i siffror 2023. Socialstyrelsen [www]. [updated 2024-04-26, cited 2024-01-31].

  4. Tarceva (erlotinib). Summary of Product Characteristics. European Medicines Agency [updated 2020-02-22, cited 2025-01-23].

  5. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-42.

  6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32.

  7. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-9.

  8. Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013;8(3):e59314.

  9. Vergnenègre A, Monnet I, Chouaïd C, Hureaux J, Mazières J, Quéré G et al. Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study. Lung Cancer. 2011;74(2):264-7.

  10. Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol. 2013;19(28):4511-9.

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  3. Socialstyrelsen. Cancer i siffror 2023. Socialstyrelsen [www]. [updated 2024-04-26, cited 2024-01-31].
  4. Tarceva (erlotinib). Summary of Product Characteristics. European Medicines Agency [updated 2020-02-22, cited 2025-01-23].
  5. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-42.
  6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32.
  7. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-9.
  8. Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013;8(3):e59314.
  9. Vergnenègre A, Monnet I, Chouaïd C, Hureaux J, Mazières J, Quéré G et al. Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study. Lung Cancer. 2011;74(2):264-7.
  10. Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol. 2013;19(28):4511-9.
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]